(Total Views: 525)
Posted On: 01/29/2021 4:08:47 PM
Post# of 145247
![](/m/assets/46931549/no_avatar_available_thumb.jpg)
"Nader Pourhassan, Ph.D., President and Chief Executive Officer of CytoDyn, commented, “We are very pleased to initiate sales of Vyrologix™ (leronlimab) in the Philippines as soon as we have CSP approved for patients. Under the CSP program, we will also generate significant data from Philippine patients with COVID-19. We continue to look forward to unblinding the data from our Phase 2b/3 clinical trial very soon and remain optimistic given the results from many eIND patients in the U.S.A., who were in a similar clinical condition as the patients in our CD12 trial.”
"initiate sales"
"initiate sales"
![](/m/images/thumb-up.png)
![](/m/images/thumb-down.png)